Neoadjuvant chemotherapy (NAC) for Pancreatic Cancer

Phase-Based Progress Estimates
Pancreatic CancerNeoadjuvant chemotherapy (NAC) - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will study whether the combination of Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA) and Neoadjuvant chemotherapy (NAC) is a feasible and tolerable treatment for Pancreatic Ductal Adenocarcinoma (PDAC), and what effect it has on the tumor.

Eligible Conditions
  • Pancreatic Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: 4 months after the initiation of chemotherapy

Month 4
Radiographic treatment response as assessed by standard Response evaluation criteria in solid tumors (RECIST) criteria
During procedure
The proportion of resectable PDAC patients that complete neoadjuvant chemotherapy + EUS RFA and undergo surgical resection.
Month 6
Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resection
Year 5
Disease-free survival time
Day 90
Number of participants with post-operative complications

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency a...
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Neoadjuvant chemotherapy (NAC) · No Placebo Group · Phase 2

Neoadjuvant chemotherapy (NAC) plus Endoscopic Ultrasound (EUS) Radiofrequency ablation (RFA)Experimental Group · 2 Interventions: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant chemotherapy (NAC) · Intervention Types: Device, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months after the initiation of chemotherapy

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
809 Previous Clinical Trials
256,170 Total Patients Enrolled
Nirav ThosaniPrincipal InvestigatorThe University of Texas Health Science Center, Houston

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have no prior chemotherapy or less than 2 months of pre-operative chemotherapy for pancreatic cancer.
You have a performance status of 0-2.